Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 46
- Registration Number
- NCT02325986
- Locations
- 🇨🇳
SYSU Cancer Center, Guangzhou, Guangdong, China
Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 20
- Registration Number
- NCT02325401
- Locations
- 🇺🇸
University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 47
- Registration Number
- NCT02324543
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
- Conditions
- Gastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2014-12-10
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 645
- Registration Number
- NCT02314117
- Locations
- 🇺🇸
UT Southwestern Med Ctr, Dallas, Texas, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients
- Conditions
- Cancer of Cervix
- Interventions
- First Posted Date
- 2014-12-05
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Professor Fernando Figueira Integral Medicine Institute
- Target Recruit Count
- 50
- Registration Number
- NCT02309658
- Locations
- 🇧🇷
Instituto de Medicina Integral Fernando Figueira, Recife, Pernambuco, Brazil
Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University College, London
- Target Recruit Count
- 70
- Registration Number
- NCT02308072
- Locations
- 🇬🇧
Velindre Cancer Centre, Wales, United Kingdom
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
- Conditions
- Squamous Cell Carcinoma of the Penis, Usual Type
- Interventions
- Drug: PaclitaxelProcedure: ILND - Inguinal Lymph Node DissectionProcedure: Prophylactic PLND - pelvic lymph node dissectionRadiation: Intensity modulated radiation treatment (IMRT)Drug: IfosfamideDrug: Cisplatin
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 200
- Registration Number
- NCT02305654
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Grady Health System, Atlanta, Georgia, United States
Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- He Xia
- Target Recruit Count
- 120
- Registration Number
- NCT02301208
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
- Conditions
- Bladder CancerCarcinoma, Transitional CellRenal Pelvis CancerUreter CancerUrethra Cancer
- Interventions
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2019-08-01
- Target Recruit Count
- 10
- Registration Number
- NCT02300610
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
- Conditions
- Carcinoma, SquamousSquamous Cell CarcinomaOropharyngeal NeoplasmsOropharyngeal Cancer
- Interventions
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Julie E. Bauman, MD, MPH
- Registration Number
- NCT02298595
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.